Abstract:Colorectal cancer remains a major public health concern and there is a continuing need to refine and develop effective strategies for early detection and prevention, particularly in populations at higher than average risk. Our study investigates the effectiveness and benefits of Fecal Immunochemical Test (FIT) surveillance in individuals with high‐risk for colorectal cancer. Key findings from our study indicate that FIT surveillance in high‐risk population demonstrates promising results in terms of early detection and prevention of colorectal cancer and advanced colorectal neoplasia. Background Current guidelines recommend colonoscopy‐based surveillance to decrease the risk of colorectal cancer (CRC) among these participants with above‐average risk. The fecal immunochemical test (FIT) holds promise as a viable alternative surveillance tool, but the existing evidence regarding the use of settings remains limited. Therefore, our aim is to evaluate the CRC incidence rates in individuals with above‐average CRC risk and the relationship between FIT surveillance and CRC incidence. Methods The retrospective cohort study was performed based on the CRC screening program between January 2012 and December 2022, in Tianjin, China. This cohort study included 12,515 participants aged 40–74 years with above‐average risk. The primary outcomes were the incidence rates of CRC and advanced colorectal neoplasia which were expressed as the number of events per 100,000 person‐years. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. Results We included 12,515 participants aged 40–74 years, of whom 4980 received subsequent FIT surveillance during the study period. Among these participants, 51 CRC cases occurred in the non‐FIT surveillance group (incidence rate, 233.88 per 100,000 person‐years) and there were 29 cases of CRC in the FIT surveillance group (incidence rate, 184.85 per 100,000 person‐years), resulting in an incidence rate ratio (IRR) of 0.58 (95% CI, 0.37–0.91). Meanwhile, 428 advanced colorectal neoplasia cases were reported in the non‐FIT surveillance group, while 269 cases occurred in the FIT surveillance group, with significantly lower incidence of advanced colorectal neoplasia in the FIT surveillance group (IRR: 0.64; 95% CI, 0.55–0.74). Compared with the non‐FIT surveillance group, the FIT surveillance group had a 54% decreased risk of developing CRC (HR, 0.46; 95% CI, 0.29–0.74) and a 45% decreased risk of developing advanced colorectal neoplasia (HR, 0.55; 95% CI, 0.47–0.64). Conclusions In this retrospective cohort study, above‐average risk individuals who received subsequent FIT in the intervals between colonoscopies were associated with a reduction of CRC and advanced colorectal neoplasia incidence, which indicated the value and utility of FIT in the surveillance program.

Effective strategies for Fecal Immunochemical Tests (FIT) programs to improve colorectal cancer screening uptake among populations with limited access to the healthcare system: a rapid review

Yield and Effectiveness of 2-Sample Fecal Immunochemical Test-Based Screening Program for Colorectal Cancer.

Barriers and facilitators to faecal immunochemical testing in symptomatic populations: A rapid systematic scoping review and gap analysis

Barriers and facilitators of implementing a multicomponent intervention to improve faecal immunochemical test (FIT) colorectal cancer screening in primary care clinics, Alberta

Improving colorectal cancer screening in rural primary care: Preliminary effectiveness and implementation of a collaborative mailed fecal immunochemical test pilot

Value of Fecal Immunochemical Test in Colorectal Cancer Screening

Factors Associated With Mailed Fecal Immunochemical Test Completion in an Integrated Academic-Community Healthcare System

Fecal Immunochemical Test Screening: Maximizing Success by Minimizing Failure

FIT as a population-based and financially viable method to screen underserved patients for colorectal cancer.

Program Components and Results From an Organized Colorectal Cancer Screening Program Using Annual Fecal Immunochemical Testing

Feasibility and Colonoscopy Yield using the Fecal Immunochemical Test (FIT)-based Colorectal Screening in a Latin America Country

Improving Fecal Immunochemical Test Collection for Colorectal Cancer Screening During the COVID-19 Pandemic

Yield and Effectiveness of Two-Sample Fecal Immunochemical Test-based Screening Program for Colorectal Cancer

Implementing Faecal Immunochemical Testing in Primary Care

S543 Exploring Reach of Colorectal Cancer Screening Methods: A Comparison of Clinical and Sociodemographic Factors Among Patients Completing Mailed FIT vs In-Clinic FIT

A Global Evaluation of the Performance Indicators of Colorectal Cancer Screening with Fecal Immunochemical Tests and Colonoscopy: A Systematic Review and Meta-Analysis

Enhancing colorectal cancer screening in high‐risk population through fecal immunochemical test surveillance: Results from a surveillance program

Possible Value of Faecal Immunochemical Test (FIT) When Added in Symptomatic Patients Referred for Colonoscopy: A Systematic Review

Colorectal cancer population screening programs worldwide in 2016: An update

Advances in tests for colorectal cancer screening and diagnosis

Faecal immunochemical test (FIT) based prioritisation of new patient symptomatic cases referred for colorectal investigation